Achieve Life Sciences completed the transfer of the analytical method for its investigational drug cytisinicline to Adare Pharma Solutions’ Vandalia, Ohio facility and produced the first engineering batch at that site. The transfer ensures that all testing procedures are fully qualified under U.S. regulatory standards, a critical step toward commercial production.
The move to a domestic contract manufacturer was prompted by FDA observations that a third‑party plant received an Official Action Indicated (OAI) classification during a cGMP inspection. By shifting production to Adare, Achieve mitigates supply‑chain risks, complies with recent tariff measures on imported pharmaceuticals, and satisfies the FDA’s expectation of a Complete Response Letter by the June 20 2026 PDUFA target date.
With the engineering batch completed, Achieve plans to resubmit its New Drug Application naming Adare as the commercial manufacturer in the fourth quarter of 2026. The company reiterated that, if approved, cytisinicline will launch in the first half of 2027, positioning the drug to capture the U.S. nicotine‑dependence market while addressing the FDA’s manufacturing concerns.
The U.S. nicotine‑dependence market includes approximately 25 million smokers and 18 million e‑cigarette users. Cytisinicline aims to be the first FDA‑approved treatment for smoking cessation in nearly 20 years and the first for vaping cessation, offering a significant opportunity in a large unmet‑needs segment.
Financially, Achieve reported a net loss of $14.7 million for Q4 2025 and held $36.4 million in cash reserves as of December 31 2025. The company’s earnings per share of –$0.28 met consensus estimates of –$0.28, indicating that its cost structure and operating performance remained in line with analyst expectations.
"The completion of the analytical transfer and the first batch now in the manufacturing site firmly positions Achieve to meet the goal of manufacturing cytisinicline drug product in the U.S. This rapid progress reflects the sense of urgency for a strong domestic supply chain given the significant tariffs recently announced on imported pharmaceutical products and the growing imperative for supply chain resilience." – Rick Stewart, CEO, Achieve Life Sciences
"Achieve is fully committed to bringing cytisinicline to the millions of people who continue to struggle with nicotine dependence and need a new solution to help them quit. Much like GLP‑1 therapies have transformed the way obesity is treated, shifting it from a lifestyle issue to a recognized medical condition, smoking cessation deserves the same evolution." – Rick Stewart, CEO, Achieve Life Sciences
"We are excited to have partnered with Achieve, reflecting our shared commitment to advancing transformative therapies and delivering meaningful impact for patients in need." – Tom Sellig, CEO, Adare Pharma Solutions
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.